Cargando…
Challenging the standard of care in advanced melanoma: focus on pembrolizumab
The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability t...
Autores principales: | Abdul-Karim, Raghad M, Cowey, C Lance |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626384/ https://www.ncbi.nlm.nih.gov/pubmed/29026335 http://dx.doi.org/10.2147/CMAR.S92546 |
Ejemplares similares
-
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018) -
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma
por: John, Lijo, et al.
Publicado: (2015) -
Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis
por: Cowey, Charles Lance, et al.
Publicado: (2021) -
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010) -
Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)